Sugi Predict

Sugi Predict / Compounds / SCHEMBL1557057

SCHEMBL1557057

SCHEMBL1557057

CC(C)(C)OC(=O)NCCCNCCCNC(=O)OC(C)(C)C

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.67
▸ MAOA P21397 1/20 0.67
▸ MAOB P27338 1/20 0.67
▸ MEN1 O00255 1/20 0.62
▸ GAA P10253 1/20 0.62
▸ KMT2A Q03164 1/20 0.62
▸ CA2 P00918 10/20 0.54
▸ CA1 P00915 9/20 0.54
▸ CA12 O43570 7/20 0.54
▸ CA9 Q16790 7/20 0.54
▸ STK17B O94768 1/20 0.48
▸ STK17A Q9UEE5 1/20 0.48
▸ EPHX1 P07099 1/20 0.46
▸ HTT P42858 1/20 0.45
▸ CA3 P07451 1/20 0.44
▸ CA4 P22748 1/20 0.44
▸ CA6 P23280 1/20 0.44
▸ CA5A P35218 1/20 0.44
▸ CA7 P43166 1/20 0.44
▸ CA14 Q9ULX7 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1298855 0.98 TDP1 (0.70) TDP1MAOAMAOBMEN1GAA
SCHEMBL18347560 0.98 TDP1 (0.70) TDP1MAOAMAOBMEN1GAA
SCHEMBL13247413 0.96 MAOA (0.63) TDP1MAOAMAOBMEN1GAA
SCHEMBL25351500 0.96 TDP1 (0.73) TDP1MAOAMAOBMEN1GAA
SCHEMBL25352741 0.96 TDP1 (0.73) TDP1MAOAMAOBMEN1GAA
SCHEMBL25353626 0.96 TDP1 (0.73) TDP1MAOAMAOBMEN1GAA
SCHEMBL18074376 0.96 TDP1 (0.72) TDP1MAOAMAOBMEN1GAA
SCHEMBL23085388 0.94 TDP1 (0.76) TDP1MAOAMAOBMEN1GAA
SCHEMBL22558007 0.94 TDP1 (0.76) TDP1MAOAMAOBMEN1GAA
SCHEMBL29832869 0.94 TDP1 (0.76) TDP1MAOAMAOBMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122036541-A Amino acid-based ionizable lipid compound, and preparation method and application thereof 中国科学院广州生物医药与健康研究院 2026-05-15 — — CN disclosed
US-20260132164-A1 PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC (US) 2026-05-14 — — US disclosed
US-12594345-B2 Degradable hyaluronic acid hydrogels ASCENDIS PHARMA A/S (DK) 2026-04-07 — — US disclosed
EP-4482583-B1 ZWITTERIONIC ANTIBACTERIAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2026-04-01 — — EP disclosed
EP-4704914-A1 ANTI-TROP2 ANTIBODY-DRUG CONJUGATES COMPRISING PNU-159682 DERIVATIVES Merck Sharp & Dohme LLC (US) 2026-03-11 — — EP disclosed
EP-4695237-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS F. Hoffmann-La Roche AG (CH) 2026-02-18 — — EP disclosed
US-12540148-B2 Lipophosphonoxins, their preparation and use USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2026-02-03 — — US disclosed
EP-4608398-A1 PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF Merck Sharp & Dohme LLC (US) 2025-09-03 — — EP disclosed
US-20250255973-A1 HYDROGEL CROSS-LINKED HYALURONIC ACID PRODRUG COMPOSITIONS AND METHODS ASCENDIS PHARMA GMBH (DE) 2025-08-14 — — US disclosed
EP-4595982-A1 MONOCONJUGATES AND THEIR PROCESS OF PREPARATION Syndivia (FR) 2025-08-06 — — EP disclosed
US-20090048147-A1 NITROGEN-BASED LINKERS FOR ATTACHING MODIFYING GROUPS TO POLYPEPTIDES AND OTHER MACROMOLECULES AFFYMAX, INC. (US) 2009-02-19 — — US disclosed
US-20090048147-A1 NITROGEN-BASED LINKERS FOR ATTACHING MODIFYING GROUPS TO POLYPEPTIDES AND OTHER MACROMOLECULES AFFYMAX, INC. (US) 2009-02-19 — — US disclosed
WO-2008095004-A2 NITROGEN-BASED LINKERS FOR ATTACHING MODIFYING GROUPS TO POLYPEPTIDES AND OTHER MACROMOLECULES AFFYMAX, INC. (US) 2008-08-07 — — WO disclosed
US-7202269-B2 GlyT2 modulators JANSSEN PHARMACEUTICA N.V. (BE) 2007-04-10 — — US disclosed
US-20050119245-A1 GlyT2 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2005-06-02 — — US disclosed
WO-2005044810-A1 GLYT2 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2005-05-19 — — WO disclosed
US-5500410-A BACTERICIDES GRUPPO LEPETIT S.P.A. (IT) 1996-03-19 — — US disclosed
EP-0465481-B1 NEW SUBSTITUTED ALKYLAMIDE DERIVATIVES OF TEICOPLANIN LEPETIT SPA (IT) 1993-11-18 — — EP disclosed
EP-0465481-A1 NEW SUBSTITUTED ALKYLAMIDE DERIVATIVES OF TEICOPLANIN. LEPETIT SPA (IT) 1992-01-15 — — EP disclosed
WO-1990011300-A1 NEW SUBSTITUTED ALKYLAMIDE DERIVATIVES OF TEICOPLANIN GRUPPO LEPETIT S.P.A. (IT) 1990-10-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119245-A1 GlyT2 modulators GLRB, GLRA1, GLRA2 TDP1 806/4885MAOA 4682/4885MAOB 4428/4885
US-20090048147-A1 NITROGEN-BASED LINKERS FOR ATTACHING MODIFYING GROUPS TO POLYPEPTIDES AND OTHER MACROMOLECULES NGLY1, YWHAZ, HBZ TDP1 1986/4885MAOA 3750/4885MAOB 3496/4885
US-12594345-B2 Degradable hyaluronic acid hydrogels CD44, H1-0, MMP1 TDP1 1693/4885MAOA 1004/4885MAOB 1730/4885
US-20250255973-A1 HYDROGEL CROSS-LINKED HYALURONIC ACID PRODRUG COMPOSITIONS AND METHODS CD44, HCAR3, HPSE TDP1 1956/4885MAOA 2407/4885MAOB 2629/4885
US-20260132164-A1 PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF TOP1, NCL, NOLC1 TDP1 216/4885MAOA 3549/4885MAOB 2895/4885
US-12540148-B2 Lipophosphonoxins, their preparation and use PLD1, LYPLA1, LPAR3 TDP1 2869/4885MAOA 3320/4885MAOB 2601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.